TrialBreast cancer research and treatment2021

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.

Matthew P Goetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.